Clinical Trial Update: A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

The document reports a Phase 2 safety study of ZD4054 (zibotentan) in patients with metastatic hormone-resistant prostate cancer; the trial status is terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Zibotentan (ZD4054) (Zibotentan)

Snippet

Sponsor: Aarhus University Hospital | Conditions: Prostate Cancer, Metastasis | Phase 2 | Status: TERMINATED